Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Capital Expenditures (2016 - 2025)

Collegium Pharmaceutical has reported Capital Expenditures over the past 10 years, most recently at $5000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $5000.0 for Q4 2025, up 100.56% from a year ago — trailing twelve months through Dec 2025 was $319000.0 (up 72.43% YoY), and the annual figure for FY2025 was $319000.0, up 72.43%.
  • Capital Expenditures for Q4 2025 was $5000.0 at Collegium Pharmaceutical, down from $190000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for COLL hit a ceiling of $940000.0 in Q4 2022 and a floor of -$897000.0 in Q4 2024.
  • Median Capital Expenditures over the past 5 years was $217000.0 (2024), compared with a mean of $212300.0.
  • Peak annual rise in Capital Expenditures hit 382.14% in 2024, while the deepest fall reached 641.32% in 2024.
  • Collegium Pharmaceutical's Capital Expenditures stood at $515000.0 in 2021, then surged by 82.52% to $940000.0 in 2022, then tumbled by 112.87% to -$121000.0 in 2023, then plummeted by 641.32% to -$897000.0 in 2024, then soared by 100.56% to $5000.0 in 2025.
  • The last three reported values for Capital Expenditures were $5000.0 (Q4 2025), $190000.0 (Q3 2025), and -$674000.0 (Q2 2025) per Business Quant data.